News | August 23, 2024
Lupin receives Health Canada approval for biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Subscribe To Our Newsletter & Stay Updated
